Neovasc Inc. Reports Results of Annual General Meeting of Shareholders

Vancouver, BC, Canada – (NewMediaWire) – June 3, 2021 – Neovasc Inc.(Neovasc or the Company) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on June 3, 2021 in Vancouver, B.C. (the Meeting).

At the Meeting, the shareholders of the Company (the Shareholders) re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko and Fred Colen to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:

At the Meeting, the Shareholders also approved the unallocated options under the Company’s stock option plan (90.49% of votes cast in favor) and re-appointed Grant Thornton LLP, Chartered Accountants as auditors of the Company.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and TiaraTM for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com

Investors

Mike Cavanaugh
Westwicke/ICR

Phone: +1.646.877.9641
[email protected]

Media

Sean Leous
Westwicke/ICR

Phone: +1.646.866.4012
[email protected]

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and applicable Canadian securities laws that may not be based on
historical fact. When used herein, the words “expect”,
“anticipate”, “estimate”, “may”,
“will”, “should”, “intend,” “believe”,
and similar expressions, are intended to identify forward-looking statements.
Forward-looking statements may involve but are not limited to, expectations as
to the growing cardiovascular marketplace. Forward-looking statements are based
on estimates and assumptions made by the Company in light of its experience and
its perception of historical trends, current conditions and expected future
developments, as well as other factors that the Company believes are
appropriate in the circumstances. Many factors could cause the Company’s actual
results, performance or achievements to differ materially from those expressed
or implied by the forward looking statements, including those described in the
“Risk Factors” section of the Company’s Annual Information Form and
in the Management’s Discussion and Analysis for the three months ended March
31, 2021 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered
carefully, and readers should not place undue reliance on the Company’s
forward-looking statements. The Company has no intention and undertakes no
obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.